Method for treating psoriasis by administering an anti-IL-12 antibody

Patent metadata

Field	Value
Publication number	US-9409984-B2
Application number	US-201414190893-A
Country	US
Kind code	B2
Filing date	Feb 26, 2014
Priority date	Aug 7, 2000
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.

First claim

What is claimed is:

1. A method for treating psoriasis in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12antibody, comprising a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6, wherein the antibody is a variant of the antibody comprising the heavy chain CDR1 amino acid sequence of SEQ ID NO:1, the heavy chain CDR2 amino acid sequence of SEQ ID NO:2, the heavy chain CDR3 amino acid sequence of SEQ ID NO:3, the light chain CDR1 amino acid sequence of SEQ ID NO:4, the light chain CDR2 amino acid sequence of SEQ ID NO:5, and the light chain CDR3 amino acid sequence of SEQ ID NO:6, to said animal.

2. The method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal.

3. The method according to claim 1 , wherein said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intraspinal, intrasynovial, rectal, buccal, sublingual, intranasal, and transdermal.

4. The method according to claim 1 , further comprising administering at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Assignees

• Janssen Biotech Inc

Inventors

• Giles-Komar Jill
• Knight David M
• Peritt David
• Scallon Bernard
• Shealy David

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title